Valuation: MannKind Corporation

Market Cap 1.31B 1.13B 1.06B 967M 1.82B 125B 1.84B 12.47B 4.89B 62.71B 4.91B 4.81B 209B P/E 2026 *
-22.3x
P/E 2027 * -3,256x
Enterprise Value 1.31B 1.13B 1.06B 967M 1.82B 125B 1.84B 12.47B 4.89B 62.71B 4.91B 4.81B 209B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 2.6x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day+4.36%
1 week+5.99%
Current month+4.09%
1 month+0.99%
3 months+36.12%
6 months-25.18%
Current year-28.22%
1 week 3.63
Extreme 3.63
4.1
1 month 3.63
Extreme 3.63
4.24
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Sell

Director

-39,051 0.0122%
17/7/26 Sell

General Counsel

-24,109 0.0078%
17/7/26 Sell

Director

-52,485 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
+4.36%+5.99%+6.82%-18.27% 1.31B
+0.17%+4.35%+72.39%+114.97% 73.45B
+1.73%+16.15%+51.73%+93.89% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.52%+4.68%+60.64%+20.20% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
0.00%+5.57%+39.57%-14.30% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.69%-1.23%+14.47%+514.12% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average +0.31%+2.94%+51.36%+176.14% 28.18B
Weighted average by Cap. +0.23%+4.97%+55.77%+163.83%

Financials

2026 *2027 *
Net sales 443M 383M 360M 328M 616M 42.49B 625M 4.23B 1.66B 21.25B 1.66B 1.63B 70.78B 504M 435M 410M 372M 700M 48.29B 710M 4.8B 1.88B 24.15B 1.89B 1.85B 80.45B
Net income -57.18M -49.38M -46.46M -42.23M -79.43M -5.48B -80.59M -545M -214M -2.74B -215M -210M -9.13B 27.12K 23.42K 22.04K 20.03K 37.67K 2.6M 38.23K 259K 101K 1.3M 102K 99.61K 4.33M
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
18/08/26 USD 4.070 +4.36% 4,600,594
17/08/26 USD 3.900 +1.30% 3,322,307
14/08/26 USD 3.850 +3.22% 2,855,400
13/08/26 USD 3.730 -3.12% 5,239,892
12/08/26 USD 3.850 +0.26% 3,055,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.070USD
Average target price
7.969USD
Spread / Average Target
+95.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock